SOPHiA GENETICS may be at an inflection point as big hospital labs and drugmakers start using its cloud software to turn genetic data into everyday clinical decisions. The upside comes from larger, longer contracts and stickier relationships, but tougher competition, slow rollouts, and shifting data rules could derail the path to consistent profits.Read more
SOPHiA GENETICS is riding the shift toward precision medicine, as more hospitals and labs turn to cloud software to turn complex health data into usable answers. A big drugmaker partnership and expanding use cases could unlock faster growth, but ongoing losses, a small set of key customers, and tighter data rules could still derail the story.Read more
SOPHiA GENETICS rides the wave of data-driven healthcare, but its sales can take a long time to turn into revenue because customers need complex setup and milestone-based deals. Currency swings, heavy upfront spending, and tougher competition could keep profits out of reach even as adoption and partnerships grow.Read more
No trending discussion available.
SOPHiA GENETICS SA operates as a cloud-native software technology company in the healthcare space. It offers SOPHiA DDM platform, a cloud-native software platform for analyzing data and generating insights from multimodal data sets and diagnostic modalities. Its SOPHiA DDM platform and related solutions, applications, products, and services are used by hospitals, laboratories, and biopharmaceutical companies through its own sales force as well as distributors and industry collaborators in Switzerland, France, Italy, rest of Europe, North America, the United States, Latin America, and the Asia-pacific. The company has a partnership with Synnovis to bring blood-based cancer testing to patients in the United Kingdom and a collaboration with AstraZeneca to develop, validate, and deploy two companion diagnostics (CDx) supporting precision oncology therapies. The company was incorporated in 2011 and is based in Rolle, Switzerland.
